Cargando…
Clinical and laboratory characteristics of clozapine-treated patients with schizophrenia referred to a national immunodeficiency clinic reveals a B-cell signature resembling common variable immunodeficiency (CVID)
AIMS: An association between antibody deficiency and clozapine use in individuals with schizophrenia has recently been reported. We hypothesised that if clozapine-associated hypogammaglobulinaemia was clinically relevant this would manifest in referral patterns. METHODS: Retrospective case note revi...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476264/ https://www.ncbi.nlm.nih.gov/pubmed/32094276 http://dx.doi.org/10.1136/jclinpath-2019-206235 |
_version_ | 1783579672348459008 |
---|---|
author | Ponsford, Mark James Steven, Rachael Bramhall, Kathyrn Burgess, Mathew Wijetilleka, Sonali Carne, Emily McGuire, Frances Price, Colin R Moody, Mo Zouwail, Soha Tahir, Tayyeb Farewell, Daniel El-Shanawany, Tariq Jolles, Stephen R A |
author_facet | Ponsford, Mark James Steven, Rachael Bramhall, Kathyrn Burgess, Mathew Wijetilleka, Sonali Carne, Emily McGuire, Frances Price, Colin R Moody, Mo Zouwail, Soha Tahir, Tayyeb Farewell, Daniel El-Shanawany, Tariq Jolles, Stephen R A |
author_sort | Ponsford, Mark James |
collection | PubMed |
description | AIMS: An association between antibody deficiency and clozapine use in individuals with schizophrenia has recently been reported. We hypothesised that if clozapine-associated hypogammaglobulinaemia was clinically relevant this would manifest in referral patterns. METHODS: Retrospective case note review of patients referred and assessed by Immunology Centre for Wales (ICW) between January 2005 and July 2018 with extraction of clinical and immunological features for individuals with diagnosis of schizophrenia-like illness. RESULTS: 1791 adult patients were assessed at ICW during this period; 23 patients had a psychiatric diagnosis of schizophrenia or schizoaffective disorder. Principal indications for referral were findings of low calculated globulin and immunoglobulins. Clozapine was the single most commonly prescribed antipsychotic (17/23), disproportionately increased relative to reported use in the general schizophrenia population (OR 6.48, 95% CI: 1.79 to 23.5). Clozapine therapy was noted in 6/7 (86%) of patients subsequently requiring immunoglobulin replacement therapy (IgRT). Marked reduction of class-switched memory B cells (CSMB) and plasmablasts were observed in clozapine-treated individuals relative to healthy age-matched controls. Clozapine duration is associated with CSMB decline. One patient discontinued clozapine, with gradual recovery of IgG levels without use of IgRT. CONCLUSIONS: Our findings are consistent with enrichment of clozapine-treatment within schizophrenic individuals referred for ICW assessment over the last 13 years. These individuals displayed clinical patterns closely resembling the primary immunodeficiency common variable immunodeficiency, however appears reversible on drug cessation. This has diagnostic, monitoring and treatment implications for psychiatry and immunology teams and directs prospective studies to address causality and the wider implications for this patient group. |
format | Online Article Text |
id | pubmed-7476264 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-74762642020-09-30 Clinical and laboratory characteristics of clozapine-treated patients with schizophrenia referred to a national immunodeficiency clinic reveals a B-cell signature resembling common variable immunodeficiency (CVID) Ponsford, Mark James Steven, Rachael Bramhall, Kathyrn Burgess, Mathew Wijetilleka, Sonali Carne, Emily McGuire, Frances Price, Colin R Moody, Mo Zouwail, Soha Tahir, Tayyeb Farewell, Daniel El-Shanawany, Tariq Jolles, Stephen R A J Clin Pathol Original Research AIMS: An association between antibody deficiency and clozapine use in individuals with schizophrenia has recently been reported. We hypothesised that if clozapine-associated hypogammaglobulinaemia was clinically relevant this would manifest in referral patterns. METHODS: Retrospective case note review of patients referred and assessed by Immunology Centre for Wales (ICW) between January 2005 and July 2018 with extraction of clinical and immunological features for individuals with diagnosis of schizophrenia-like illness. RESULTS: 1791 adult patients were assessed at ICW during this period; 23 patients had a psychiatric diagnosis of schizophrenia or schizoaffective disorder. Principal indications for referral were findings of low calculated globulin and immunoglobulins. Clozapine was the single most commonly prescribed antipsychotic (17/23), disproportionately increased relative to reported use in the general schizophrenia population (OR 6.48, 95% CI: 1.79 to 23.5). Clozapine therapy was noted in 6/7 (86%) of patients subsequently requiring immunoglobulin replacement therapy (IgRT). Marked reduction of class-switched memory B cells (CSMB) and plasmablasts were observed in clozapine-treated individuals relative to healthy age-matched controls. Clozapine duration is associated with CSMB decline. One patient discontinued clozapine, with gradual recovery of IgG levels without use of IgRT. CONCLUSIONS: Our findings are consistent with enrichment of clozapine-treatment within schizophrenic individuals referred for ICW assessment over the last 13 years. These individuals displayed clinical patterns closely resembling the primary immunodeficiency common variable immunodeficiency, however appears reversible on drug cessation. This has diagnostic, monitoring and treatment implications for psychiatry and immunology teams and directs prospective studies to address causality and the wider implications for this patient group. BMJ Publishing Group 2020-09 2020-02-24 /pmc/articles/PMC7476264/ /pubmed/32094276 http://dx.doi.org/10.1136/jclinpath-2019-206235 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Research Ponsford, Mark James Steven, Rachael Bramhall, Kathyrn Burgess, Mathew Wijetilleka, Sonali Carne, Emily McGuire, Frances Price, Colin R Moody, Mo Zouwail, Soha Tahir, Tayyeb Farewell, Daniel El-Shanawany, Tariq Jolles, Stephen R A Clinical and laboratory characteristics of clozapine-treated patients with schizophrenia referred to a national immunodeficiency clinic reveals a B-cell signature resembling common variable immunodeficiency (CVID) |
title | Clinical and laboratory characteristics of clozapine-treated patients with schizophrenia referred to a national immunodeficiency clinic reveals a B-cell signature resembling common variable immunodeficiency (CVID) |
title_full | Clinical and laboratory characteristics of clozapine-treated patients with schizophrenia referred to a national immunodeficiency clinic reveals a B-cell signature resembling common variable immunodeficiency (CVID) |
title_fullStr | Clinical and laboratory characteristics of clozapine-treated patients with schizophrenia referred to a national immunodeficiency clinic reveals a B-cell signature resembling common variable immunodeficiency (CVID) |
title_full_unstemmed | Clinical and laboratory characteristics of clozapine-treated patients with schizophrenia referred to a national immunodeficiency clinic reveals a B-cell signature resembling common variable immunodeficiency (CVID) |
title_short | Clinical and laboratory characteristics of clozapine-treated patients with schizophrenia referred to a national immunodeficiency clinic reveals a B-cell signature resembling common variable immunodeficiency (CVID) |
title_sort | clinical and laboratory characteristics of clozapine-treated patients with schizophrenia referred to a national immunodeficiency clinic reveals a b-cell signature resembling common variable immunodeficiency (cvid) |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476264/ https://www.ncbi.nlm.nih.gov/pubmed/32094276 http://dx.doi.org/10.1136/jclinpath-2019-206235 |
work_keys_str_mv | AT ponsfordmarkjames clinicalandlaboratorycharacteristicsofclozapinetreatedpatientswithschizophreniareferredtoanationalimmunodeficiencyclinicrevealsabcellsignatureresemblingcommonvariableimmunodeficiencycvid AT stevenrachael clinicalandlaboratorycharacteristicsofclozapinetreatedpatientswithschizophreniareferredtoanationalimmunodeficiencyclinicrevealsabcellsignatureresemblingcommonvariableimmunodeficiencycvid AT bramhallkathyrn clinicalandlaboratorycharacteristicsofclozapinetreatedpatientswithschizophreniareferredtoanationalimmunodeficiencyclinicrevealsabcellsignatureresemblingcommonvariableimmunodeficiencycvid AT burgessmathew clinicalandlaboratorycharacteristicsofclozapinetreatedpatientswithschizophreniareferredtoanationalimmunodeficiencyclinicrevealsabcellsignatureresemblingcommonvariableimmunodeficiencycvid AT wijetillekasonali clinicalandlaboratorycharacteristicsofclozapinetreatedpatientswithschizophreniareferredtoanationalimmunodeficiencyclinicrevealsabcellsignatureresemblingcommonvariableimmunodeficiencycvid AT carneemily clinicalandlaboratorycharacteristicsofclozapinetreatedpatientswithschizophreniareferredtoanationalimmunodeficiencyclinicrevealsabcellsignatureresemblingcommonvariableimmunodeficiencycvid AT mcguirefrances clinicalandlaboratorycharacteristicsofclozapinetreatedpatientswithschizophreniareferredtoanationalimmunodeficiencyclinicrevealsabcellsignatureresemblingcommonvariableimmunodeficiencycvid AT pricecolinr clinicalandlaboratorycharacteristicsofclozapinetreatedpatientswithschizophreniareferredtoanationalimmunodeficiencyclinicrevealsabcellsignatureresemblingcommonvariableimmunodeficiencycvid AT moodymo clinicalandlaboratorycharacteristicsofclozapinetreatedpatientswithschizophreniareferredtoanationalimmunodeficiencyclinicrevealsabcellsignatureresemblingcommonvariableimmunodeficiencycvid AT zouwailsoha clinicalandlaboratorycharacteristicsofclozapinetreatedpatientswithschizophreniareferredtoanationalimmunodeficiencyclinicrevealsabcellsignatureresemblingcommonvariableimmunodeficiencycvid AT tahirtayyeb clinicalandlaboratorycharacteristicsofclozapinetreatedpatientswithschizophreniareferredtoanationalimmunodeficiencyclinicrevealsabcellsignatureresemblingcommonvariableimmunodeficiencycvid AT farewelldaniel clinicalandlaboratorycharacteristicsofclozapinetreatedpatientswithschizophreniareferredtoanationalimmunodeficiencyclinicrevealsabcellsignatureresemblingcommonvariableimmunodeficiencycvid AT elshanawanytariq clinicalandlaboratorycharacteristicsofclozapinetreatedpatientswithschizophreniareferredtoanationalimmunodeficiencyclinicrevealsabcellsignatureresemblingcommonvariableimmunodeficiencycvid AT jollesstephenra clinicalandlaboratorycharacteristicsofclozapinetreatedpatientswithschizophreniareferredtoanationalimmunodeficiencyclinicrevealsabcellsignatureresemblingcommonvariableimmunodeficiencycvid |